What is the 13F Pro Quality Score for CLNN?

13F Pro ranks Clene Inc. (CLNN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLNN's current score at https://13fpro.ai/research/CLNN (free sign-up required for the full ranking).

Where does 13F Pro source CLNN data?

All Clene Inc. fundamentals and ownership data come directly from SEC EDGAR. Clene Inc. files with the SEC under CIK 1822791. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLNN in?

Clene Inc. (CLNN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLNN research updated on 13F Pro?

CLNN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Clene Inc.(CLNN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1822791 CLNN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CLNN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Clene Inc. (CLNN), a Healthcare sector company. CLNN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), Clene Inc. reports quarterly revenue of $15.0K, net income of $-8.1M, free cash flow of $-4.5M. Top institutional holders of CLNN by reported 13-F value include Boxer Capital Management,, SymBiosis Capital Partners,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CLNN trades on the Nasdaq exchange and files with the SEC under CIK 1822791. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLNN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Clene Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$15.0K

Net Income

Q1 2026

$-8.1M

Free Cash Flow

Q1 2026

$-4.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-69.4% YoY

$200.0KFY 2025

FY19 —FY22 $473.0KFY23 $654.0KFY25 $200.0K

Net Income

+47.1% YoY

$-26.2MFY 2025

FY19 $-16.2MFY22 $-29.9MFY23 $-49.5MFY25 $-26.2M

Operating Income

+43.1% YoY

$-23.1MFY 2025

FY19 $-16.3MFY22 $-48.4MFY23 $-40.5MFY25 $-23.1M

Total Assets

-65.4% YoY

$18.1MFY 2025

FY19 $14.9MFY22 $44.5MFY23 $52.3MFY25 $18.1M

Total Debt

$17.8MFY 2025

FY19 —FY22 —FY23 —FY25 $17.8M

Op. Cash Flow

+38.5% YoY

$-18.5MFY 2025

FY19 $-13.2MFY22 $-39.0MFY23 $-30.2MFY25 $-18.5M

Metric	FY 2025	FY 2023	FY 2022	FY 2019	FY 2018
Revenue	$200.0K -69.4%	$654.0K +38.3%	$473.0K	—	—
Net Income	$-26.2M +47.1%	$-49.5M -65.5%	$-29.9M -85.2%	$-16.2M	—
Operating Income	$-23.1M +43.1%	$-40.5M +16.3%	$-48.4M -196.4%	$-16.3M	—
Total Assets	$18.1M -65.4%	$52.3M +17.6%	$44.5M +199.1%	$14.9M	—
Total Debt	$17.8M	—	—	—	—
Operating Cash Flow	$-18.5M +38.5%	$-30.2M +22.7%	$-39.0M -195.6%	$-13.2M	—

AI Insight: CLNN Financial Trends

Clene remains pre-revenue with persistent operating losses and negative equity, though operating cash burn has stabilized around $4–5M quarterly.

• Operating income loss narrowed from $9M in Q4 2024 to $2M in Q1 2026, suggesting cost discipline as company remains pre-revenue.

• Operating cash flow stabilized at $4–5M quarterly burn (Q3 2025 onward) versus $6M average in 2024, indicating improved cash management.

• Total debt held steady at $18M since Q3 2025; equity deficit widened to negative $19M in Q1 2026 from negative $1M in Q2 2024.

⚠ Zero revenue across 9 consecutive quarters signals prolonged clinical/regulatory phase with no commercial milestone visibility yet.

⚠ Negative equity deteriorated $18M over 18 months; solvency depends entirely on capital raise or debt restructuring.

AI Insight: CLNN Ratio Trends

Data too sparse to identify meaningful trends—only two ROA readings available across nine quarters.

• ROA improved substantially from -67.3% in Q2 2024 to -11.9% in Q1 2025, signaling reduced near-term losses.

⚠ Both available ROA figures remain deeply negative; profitability trajectory unclear without more recent quarterly results.

Get alerted when CLNN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Clene Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLNN

Boxer Capital Management, LLC
$2.4M477,515 sh
SymBiosis Capital Partners, LLC
$2.1M431,094 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.5M308,230 sh
SCOGGIN MANAGEMENT LP
$1.5M300,000 sh
Ensign Peak Advisors, Inc
$1.3M257,872 sh
GEODE CAPITAL MANAGEMENT, LLC
$473.0K95,874 sh
Lunt Capital Management, Inc.
$257.6K52,260 sh
PEAK6 LLC
$246.6K50,012 sh
VANGUARD FIDUCIARY TRUST CO
$215.5K43,715 sh
PARSONS CAPITAL MANAGEMENT INC/RI
$183.6K37,243 sh

Fund	Value	Shares
Boxer Capital Management, LLC	$2.4M	477,515
SymBiosis Capital Partners, LLC	$2.1M	431,094
VANGUARD CAPITAL MANAGEMENT LLC	$1.5M	308,230
SCOGGIN MANAGEMENT LP	$1.5M	300,000
Ensign Peak Advisors, Inc	$1.3M	257,872
GEODE CAPITAL MANAGEMENT, LLC	$473.0K	95,874
Lunt Capital Management, Inc.	$257.6K	52,260
PEAK6 LLC	$246.6K	50,012
VANGUARD FIDUCIARY TRUST CO	$215.5K	43,715
PARSONS CAPITAL MANAGEMENT INC/RI	$183.6K	37,243

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLNN on your watchlist

Track score changes the day Clene Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLNN a good stock to buy?

13F Pro's AI-powered analysis of Clene Inc. (CLNN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLNN are available on the CLNN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CLNN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLNN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Clene Inc.'s investment landscape.